Global Heparin Market Highlights Over 2020 - 2030

The global heparin market is estimated to grow with a CAGR of 4.1% during the forecast period 2021-2030. The market is further expected to garner a revenue of USD 7938.6 Million by the end of 2030, up from a revenue of USD 5340 Million in 2020. The growth of the market can primarily be attributed to the growing utilization of heparin in its various forms for the treatment of venous thromboembolism/pulmonary embolism, atrial fibrillations with embolization, peripheral arterial embolism, dialysis, surgeries, and blood transfusions among others. Moreover, the rising prevalence of venous thromboembolism worldwide is also anticipated to drive the market growth during the forecast period. According to the statistics by the U.S. Centers for Disease Control and Prevention (CDC), it has been estimated that around 60,000-100,000 Americans die of deep vein thrombosis/pulmonary embolism (DVT/PE), also known as venous thromboembolism. The statistics also stated that within 10 years, 1/3^rd of the people with DVT/PE would have a recurrence of the disease. The market is also anticipated to grow on account of the growing utilization of anticoagulants for the prevention and treatment of numerous types of thromboembolic disorders, such as atrial fibrillation (AFib or AF), backed by the growing cases of such disorders worldwide. In other statistics by the U.S. CDC 175326 deaths were caused due to AFib in the year 2018 in the United States. Moreover, it has also been estimated that 12.1 Million people will have the disorder by 2030.

Get more information on this report: Download Sample PDF

Global Heparin Market Regional Synopsis

Regionally, the global heparin market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in North America region is anticipated to hold the highest market share throughout the forecast period and further attain a revenue of USD 3270.7 Million by the end of 2030, up from a revenue of USD 2188.2 Million in 2020. The market in the region is also anticipated to grow with a CAGR of 4.1% during the forecast period. The growth of the market in the region can primarily be attributed to the presence of a strong healthcare network in the region, followed by the increasing expenditure on health amongst the countries, such as the United States. According to the statistics by the World Bank, the current health expenditure as a share of GDP in the United States and Canada grew from 12.542% and 8.276% respectively in the year 2000, and is further projected to touch 16.885% and 10.79% respectively in the year 2018. CLICK TO DOWNLOAD SAMPLE REPORT 

On the other hand, the market in the Asia Pacific is expected to hold the second-leading share and also grow with the highest CAGR of 4.9% during the forecast period. The market in the Asia Pacific registered a revenue of USD 1122.8 Million in 2020 and is further projected to touch USD 1802.1 Million by the end of 2030. The market in the Asia Pacific is segmented by country into China, India, Russia, Australia, Indonesia, and the Rest of Asia Pacific. Out of these, the market in China is anticipated to garner the highest market share throughout the forecast period and further grow with a CAGR of 5% during the forecast period. The market in the country is also expected to garner a revenue of USD 672.2 Million by the end of 2030 from USD 415.1 Million in 2020.

The study further incorporates Y-O-Y Growth, market opportunities, demand & supply and forecast future opportunity in North America (United States, Canada, Mexico), South America, Europe (U.K., Germany, France, Italy, Spain, Hungary, BENELUX [Belgium, Netherlands, Luxembourg], NORDIC [Norway, Denmark, Sweden, Finland], Poland, Russia, Rest of Europe), Asia-Pacific (China, India, Japan, South Korea, Malaysia, Indonesia, Taiwan, Hong Kong, Australia, New Zealand, Rest of Asia-Pacific), Middle East and Africa (Israel, GCC [Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, Rest of Middle East and Africa).

Growth Drivers and Challenges Impacting the Growth of the Global Heparin Market

Growth Drivers

• Growing Utilization of Heparin for Treating Venous Thromboembolism
• Rapid Surge in Advancements in Medical Research

Challenges

• Stringent Norms for the Manufacturing of Heparin
• Increasing Adoption of Oral Anticoagulants

Global Heparin Market Segmentation Synopsis

The global heparin market is segmented by product into unfractionated heparin (UFH), low molecular weight heparin (LMWH), and ultra low molecular weight heparin (ULMWH). Out of these segments, the low molecular weight heparin (LMWH) segment is anticipated to hold the highest market share throughout the forecast period and further touch a revenue of USD 5154.8 Million by the end of 2030, up from USD 3493.5 Million in 2020. The market is further segmented by route of administration into intravenous injection and subcutaneous injection, out of which, the subcutaneous injection segment is expected to hold the highest market during the forecast period. Alternatively, the intravenous injection segment is expected to grow with the highest CAGR of 4.5% during the forecast period. On the basis of application, the market is segmented into clinical trials, medical devices, and venous thromboembolism, out of which, the venous thromboembolism segment is expected to garner the highest market share throughout the forecast period and further touch a revenue of USD 7032.3 Million by 2030.

Key Companies Dominating the Market

Our report has covered detailed company profiling comprising company overview, business strategies, key product offerings, financial performance, key performance indicators, risk analysis, recent developments, regional presence, and SWOT analysis among other notable indicators for competitive positioning. Some of the prominent industry leaders in the global heparin market that are included in our report are GlaxoSmithKline plc, Pfizer Inc., Aspen Holdings, Baxter International Inc., Fresenius Kabi AG, Amphastar Pharmaceuticals, Inc., Mylan N.V., Sanofi, LEO Pharma A/S, B.Braun Melsungen AG, and others.

Key Reasons to Buy Our Report

• The report covers detailed analysis comprising market share attained by each market segment and its sub-segments.
• It covers market dynamics including growth drivers, trends, potential opportunities, price trend analysis and challenges that impact the market growth.
• The report includes detailed company profiles of the major players dominating the market.
• We use effective research methodologies to calculate the market numbers and provide value-added assessment for overall growth.
• We provide customized reports as per the clients’ requirement helping them to see possible and unexpected challenges and unforeseen opportunities in order to help them reach their goal.